Abstract | INTRODUCTION: AREAS COVERED: Multitargeted kinase inhibitors are small molecule inhibitors with limited toxicity. This review will focus on early-stage investigations of multitargeted tyrosine kinase inhibitors (m-TKIs) (those that target at least two tyrosine kinases) for HNSCC. Preclinical and early trials investigating m-TKIs for various disease settings of HNSCC will be evaluated for efficacy, identification of significant biomarkers and potential for combination therapy. EXPERT OPINION: Few single agent m-TKIs have demonstrated efficacy in unselected HNSCC populations. The most promising clinical results have been obtained when m-TKIs are tested in combination with other therapies, including immunotherapy, or in mutation-defined subgroups of patients. The future success of m-TKIs will rely on identification, in preclinical models and clinical trials, of predictive biomarkers of response and mechanisms of innate and acquired resistance.
|
Authors | Ana Marija Sola, Daniel E Johnson, Jennifer R Grandis |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 28
Issue 4
Pg. 351-363
(04 2019)
ISSN: 1744-7658 [Electronic] England |
PMID | 30753792
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Drugs, Investigational
- Protein Kinase Inhibitors
|
Topics |
- Animals
- Antineoplastic Agents
(administration & dosage, adverse effects, pharmacology)
- Drug Development
(methods)
- Drugs, Investigational
(administration & dosage, adverse effects, pharmacology)
- Head and Neck Neoplasms
(drug therapy, enzymology)
- Humans
- Molecular Targeted Therapy
- Protein Kinase Inhibitors
(administration & dosage, adverse effects, pharmacology)
- Squamous Cell Carcinoma of Head and Neck
(drug therapy, enzymology)
|